Abozymes Completes Seed Financing Round To Fund Development Of Technology To Enable Universal Organ Transplants And Blood Transfusions
Jun 23, 2022•about 3 years ago
Round Type
seed
Description
ABOzymes Biomedical Inc., today announced it has completed a substantially upsized seed financing. The funds will be used to further develop its ground-breaking proprietary platform that enables a world where a patient’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions.
FundzWatch™ Score
75
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood